Last reviewed · How we verify

NCT05085821: HEART

Cardio-visual Stimulation in Augmented Reality for Pain Reduction

Completed NA Last updated 6 February 2024
What this trial tests

NA trial testing HEART in Regional Pain Syndrome in 32 participants. Completed in 29 June 2023.

Timeline
20 April 2021
Primary endpoint
29 June 2023
29 June 2023

Quick facts

Lead sponsorUnion de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingtriple
Primary purposetreatment
Enrollment32
Start date20 April 2021
Primary completion29 June 2023
Estimated completion29 June 2023
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Union de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est

Who can join

18 and older, any sex, with Regional Pain Syndrome or Chronic Pain Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to evaluate the feasibility and efficacy of an Augmented Reality (AR) biofeedback intervention to alleviate pain symptoms in individuals suffering from chronic pain of the hand and/or the forearm.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of HEART

Trials testing the same drug.

Other Union de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05085821.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing